Group B streptococcal infection future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
Rim Halaby (talk | contribs) No edit summary |
Rim Halaby (talk | contribs) |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
GBS vaccines have been investigated as a tool for reducing maternal colonization and preventing transmission to neonates;<ref name="pmid3050524">{{cite journal| author=Baker CJ, Rench MA, Edwards MS, Carpenter RJ, Hays BM, Kasper DL| title=Immunization of pregnant women with a polysaccharide vaccine of group B streptococcus. | journal=N Engl J Med | year= 1988 | volume= 319 | issue= 18 | pages= 1180-5 | pmid=3050524 | doi=10.1056/NEJM198811033191802 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=3050524 }} </ref> however, no licensed vaccine is available currently. Phase I and II clinical trials among healthy, non-pregnant adults of monovalent polysaccharide-protein conjugate [[vaccine]]s of GBS disease-associated types have shown these vaccines to be well tolerated and immunogenic.<ref name="pmid12716700">{{cite journal| author=Baker CJ, Edwards MS| title=Group B streptococcal conjugate vaccines. | journal=Arch Dis Child | year= 2003 | volume= 88 | issue= 5 | pages= 375-8 | pmid=12716700 | doi= | pmc=PMC1719562 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12716700 }} </ref><ref name="pmid10979909">{{cite journal| author=Baker CJ, Paoletti LC, Rench MA, Guttormsen HK, Carey VJ, Hickman ME et al.| title=Use of capsular polysaccharide-tetanus toxoid conjugate vaccine for type II group B Streptococcus in healthy women. | journal=J Infect Dis | year= 2000 | volume= 182 | issue= 4 | pages= 1129-38 | pmid=10979909 | doi=10.1086/315839 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10979909 }} </ref> A recent, double-blind randomized trial of a conjugate vaccine against GBS serotype III among non-pregnant women of reproductive age found a significant delay in acquisition of colonization with the [[vaccine]]-serotype among vaccine recipients.<ref name=Hilier>Hillier S, Ferris D, Fine D, Ferrieri P, et al. Women receiving group B Streptococcus serotype III tetanus toxoid (GBS III-TT) vaccine have reduced vaginal and rectal acquisition of GBS type III [Presentation]. Annual meeting of the Infectious Diseases Society of America, Philadelphia, Pennsylvania; October 20--November 1, 2009.</ref><ref name=CDCMMWR>Verani J.R., McGee L, and Schrag S.J. Prevention of Perinatal Group B Streptococcal Disease. Revised Guidelines from CDC, 2010.[http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5910a1.htm?s_cid=rr5910a1_w CDC.gov]</ref> | |||
==References== | ==References== | ||
Revision as of 15:03, 21 August 2014
|
Group B Streptococcal Infection Microchapters |
|
Differentiating Group B Streptococcal Infection from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Group B streptococcal infection future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Group B streptococcal infection future or investigational therapies |
|
FDA on Group B streptococcal infection future or investigational therapies |
|
CDC on Group B streptococcal infection future or investigational therapies |
|
Group B streptococcal infection future or investigational therapies in the news |
|
Blogs on Group B streptococcal infection future or investigational therapies |
|
Directions to Hospitals Treating Group B streptococcal infection |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2]
Overview
GBS vaccines have been investigated as a tool for reducing maternal colonization and preventing transmission to neonates;[1] however, no licensed vaccine is available currently. Phase I and II clinical trials among healthy, non-pregnant adults of monovalent polysaccharide-protein conjugate vaccines of GBS disease-associated types have shown these vaccines to be well tolerated and immunogenic.[2][3] A recent, double-blind randomized trial of a conjugate vaccine against GBS serotype III among non-pregnant women of reproductive age found a significant delay in acquisition of colonization with the vaccine-serotype among vaccine recipients.[4][5]
References
- ↑ Baker CJ, Rench MA, Edwards MS, Carpenter RJ, Hays BM, Kasper DL (1988). "Immunization of pregnant women with a polysaccharide vaccine of group B streptococcus". N Engl J Med. 319 (18): 1180–5. doi:10.1056/NEJM198811033191802. PMID 3050524.
- ↑ Baker CJ, Edwards MS (2003). "Group B streptococcal conjugate vaccines". Arch Dis Child. 88 (5): 375–8. PMC 1719562. PMID 12716700.
- ↑ Baker CJ, Paoletti LC, Rench MA, Guttormsen HK, Carey VJ, Hickman ME; et al. (2000). "Use of capsular polysaccharide-tetanus toxoid conjugate vaccine for type II group B Streptococcus in healthy women". J Infect Dis. 182 (4): 1129–38. doi:10.1086/315839. PMID 10979909.
- ↑ Hillier S, Ferris D, Fine D, Ferrieri P, et al. Women receiving group B Streptococcus serotype III tetanus toxoid (GBS III-TT) vaccine have reduced vaginal and rectal acquisition of GBS type III [Presentation]. Annual meeting of the Infectious Diseases Society of America, Philadelphia, Pennsylvania; October 20--November 1, 2009.
- ↑ Verani J.R., McGee L, and Schrag S.J. Prevention of Perinatal Group B Streptococcal Disease. Revised Guidelines from CDC, 2010.CDC.gov